HomeCompareLOUIF vs PFE

LOUIF vs PFE: Dividend Comparison 2026

LOUIF yields 20000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LOUIF wins by $52481917574412746752.00M in total portfolio value
10 years
LOUIF
LOUIF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full LOUIF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LOUIF vs PFE

📍 LOUIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLOUIFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LOUIF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LOUIF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOUIF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, LOUIF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOUIF + PFE for your $10,000?

LOUIF: 50%PFE: 50%
100% PFE50/50100% LOUIF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LOUIF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOUIF buys
0
PFE buys
0
No recent congressional trades found for LOUIF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLOUIFPFE
Forward yield20000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$52481917574412746752.00M$49.6K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$26,258.71
Total dividends collected$52448189483771600896.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LOUIF vs PFE ($10,000, DRIP)

YearLOUIF PortfolioLOUIF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,010,700$2,000,000.00$9,153$693.39+$2.00MLOUIF
2$377,983,225$375,831,775.70$8,593$849.25+$377.97MLOUIF
3$66,433,479,469$66,029,037,418.28$8,336$1,066.78+$66433.47MLOUIF
4$10,916,985,471,987$10,845,901,648,955.73$8,437$1,384.80+$10916985.46MLOUIF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$9,013$1,875.40+$1677384363.76MLOUIF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$10,306$2,680.72+$240985175079.13MLOUIF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$12,820$4,101.38+$32373573631143.68MLOUIF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$17,673$6,826.70+$4066766648320630.00MLOUIF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$27,543$12,591.86+$477730483406513344.00MLOUIF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$49,560$26,258.71+$52481917574412746752.00MLOUIF

LOUIF vs PFE: Complete Analysis 2026

LOUIFStock

South Shore Holdings Limited, an investment holding company, engages in the hospitality, entertainment, and construction businesses in Hong Kong, Macau, Singapore, and Malaysia. It operates through Management Contracting, Property Development Management, Property Investment, and Hotel Operation segments. The Management Contracting segment offers building construction and civil engineering services. The Property Development Management segment develops and manages projects, as well as provides facilities and asset management services. The Property Investment segment invests in properties. The Hotel Operation segment operates hotels with ancillary facilities. The company also offers electrical, mechanical, and building services, as well as finance, interior decoration and foundation works, and management and secretarial services. In addition, it is involved in the trade and letting of plant and machinery; and trade and installation of building materials. The company was formerly known as The 13 Holdings Limited and changed its name to South Shore Holdings Limited in June 2018. South Shore Holdings Limited was founded in 1946 and is based in Quarry Bay, Hong Kong.

Full LOUIF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LOUIF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOUIF vs SCHDLOUIF vs JEPILOUIF vs OLOUIF vs KOLOUIF vs MAINLOUIF vs JNJLOUIF vs MRKLOUIF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.